BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33838063)

  • 1. The facioscapulohumeral muscular dystrophy Rasch-built overall disability scale (FSHD-RODS).
    Mul K; Hamadeh T; Horlings CGC; Tawil R; Statland JM; Sacconi S; Corbett AJ; Voermans NC; Faber CG; van Engelen BGM; Merkies ISJ
    Eur J Neurol; 2021 Jul; 28(7):2339-2348. PubMed ID: 33838063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Val30Met familial amyloid polyneuropathy specific Rasch-built overall disability scale (FAP-RODS(©) ).
    Pruppers MH; Merkies IS; Faber CG; Da Silva AM; Costa V; Coelho T
    J Peripher Nerv Syst; 2015 Sep; 20(3):319-27. PubMed ID: 26115039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of the patient-reported "Facial Function Scale" for facioscapulohumeral muscular dystrophy.
    Mul K; Wijayanto F; Loonen TGJ; Groot P; Vincenten SCC; Knuijt S; Groothuis JT; Maal TJJ; Heskes T; Voermans NC; Engelen BGMV
    Disabil Rehabil; 2023 May; 45(9):1530-1535. PubMed ID: 35575310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving assessment in small fiber neuropathy.
    Brouwer BA; Bakkers M; Hoeijmakers JG; Faber CG; Merkies IS
    J Peripher Nerv Syst; 2015 Sep; 20(3):333-40. PubMed ID: 26114213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rasch analysis to evaluate the motor function measure for patients with facioscapulohumeral muscular dystrophy.
    Mul K; Horlings CGC; Faber CG; van Engelen BGM; Merkies ISJ
    Int J Rehabil Res; 2021 Mar; 44(1):38-44. PubMed ID: 33165002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).
    Binda D; Vanhoutte EK; Cavaletti G; Cornblath DR; Postma TJ; Frigeni B; Alberti P; Bruna J; Velasco R; Argyriou AA; Kalofonos HP; Psimaras D; Ricard D; Pace A; Galiè E; Briani C; Dalla Torre C; Lalisang RI; Boogerd W; Brandsma D; Koeppen S; Hense J; Storey D; Kerrigan S; Schenone A; Fabbri S; Rossi E; Valsecchi MG; Faber CG; Merkies IS; ; Galimberti S; Lanzani F; Mattavelli L; Piatti ML; Bidoli P; Cazzaniga M; Cortinovis D; Lucchetta M; Campagnolo M; Bakkers M; Brouwer B; Boogerd W; Grant R; Reni L; Piras B; Pessino A; Padua L; Granata G; Leandri M; Ghignotti I; Plasmati R; Pastorelli F; Heimans JJ; Eurelings M; Meijer RJ; Grisold W; Lindeck Pozza E; Mazzeo A; Toscano A; Russo M; Tomasello C; Altavilla G; Penas Prado M; Dominguez Gonzalez C; Dorsey SG
    Eur J Cancer; 2013 Sep; 49(13):2910-8. PubMed ID: 23668917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The facioscapulohumeral muscular dystrophy - health index: Italian validation of a disease-specific measure of symptomatic burden.
    Carraro E; Greco LC; Lizio A; Beretta M; Pozzi S; Casiraghi J; Becchiati S; Beshiri F; Frisoni MC; Iossa F; Heatwole C; Sansone V
    Disabil Rehabil; 2024 May; 46(10):2130-2137. PubMed ID: 37194629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rasch-built Overall Disability Scale for Multifocal motor neuropathy (MMN-RODS(©) ).
    Vanhoutte EK; Faber CG; van Nes SI; Cats EA; Van der Pol WL; Gorson KC; van Doorn PA; Cornblath DR; van den Berg LH; Merkies IS;
    J Peripher Nerv Syst; 2015 Sep; 20(3):296-305. PubMed ID: 26329270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is Going Beyond Rasch Analysis Necessary to Assess the Construct Validity of a Motor Function Scale?
    Guillot T; Roche S; Rippert P; Hamroun D; Iwaz J; Ecochard R; Vuillerot C;
    Arch Phys Med Rehabil; 2018 Sep; 99(9):1776-1782.e9. PubMed ID: 29625093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rasch-built overall disability scale for POEMS syndrome (POEMS-RODS).
    Keh RYS; Lilleker JB; Lavin T; Sive J; D'Sa S; Ramdharry G; Carr AS; Lunn MP
    J Peripher Nerv Syst; 2022 Dec; 27(4):302-310. PubMed ID: 36190435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Facioscapulohumeral Muscular Dystrophy-Health Index: Development and evaluation of a disease-specific outcome measure.
    Varma A; Weinstein J; Seabury J; Rosero S; Engebrecht C; Wagner E; Zizzi C; Luebbe EA; Dilek N; McDermott MP; Kissel J; Sansone V; Heatwole C
    Muscle Nerve; 2023 Oct; 68(4):422-431. PubMed ID: 37610084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS).
    Fournier CN; Bedlack R; Quinn C; Russell J; Beckwith D; Kaminski KH; Tyor W; Hertzberg V; James V; Polak M; Glass JD
    JAMA Neurol; 2020 Apr; 77(4):480-488. PubMed ID: 31886839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An instrumented timed up and go in facioscapulohumeral muscular dystrophy.
    Huisinga J; Bruetsch A; Mccalley A; Currence M; Herbelin L; Jawdat O; Pasnoor M; Dimachkie M; Barohn R; Statland J
    Muscle Nerve; 2018 Mar; 57(3):503-506. PubMed ID: 28877559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reliability and validity of the FSHD-composite outcome measure in childhood facioscapulohumeral dystrophy.
    de Valle K; Dobson F; Woodcock I; Carroll K; Ryan MM; Heatwole C; Eichinger K; McGinley JL
    Neuromuscul Disord; 2021 Aug; 31(8):706-715. PubMed ID: 34210539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upper limb function and activity in people with facioscapulohumeral muscular dystrophy: a web-based survey.
    Bergsma A; Cup EH; Janssen MM; Geurts AC; de Groot IJ
    Disabil Rehabil; 2017 Feb; 39(3):236-243. PubMed ID: 26942834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study.
    LoRusso S; Johnson NE; McDermott MP; Eichinger K; Butterfield RJ; Carraro E; Higgs K; Lewis L; Mul K; Sacconi S; Sansone VA; Shieh P; van Engelen B; Wagner K; Wang L; Statland JM; Tawil R;
    BMC Neurol; 2019 Sep; 19(1):224. PubMed ID: 31506080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facioscapulohumeral muscular dystrophy functional composite outcome measure.
    Eichinger K; Heatwole C; Iyadurai S; King W; Baker L; Heininger S; Bartlett A; Dilek N; Martens WB; Mcdermott M; Kissel JT; Tawil R; Statland JM
    Muscle Nerve; 2018 Jan; ():. PubMed ID: 29381807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reconstructing the Rasch-Built Myotonic Dystrophy Type 1 Activity and Participation Scale.
    Hermans MC; Hoeijmakers JG; Faber CG; Merkies IS
    PLoS One; 2015; 10(10):e0139944. PubMed ID: 26484877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facioscapulohumeral muscular dystrophy Health Index: Japanese translation and validation study.
    Fujino H; Takahashi MP; Nakamura H; Heatwole CR; Takada H; Kuru S; Ogata K; Enomoto K; Hayashi Y; Imura O; Matsumura T
    Disabil Rehabil; 2024 Mar; ():1-10. PubMed ID: 38555736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrical impedance myography in facioscapulohumeral muscular dystrophy.
    Statland JM; Heatwole C; Eichinger K; Dilek N; Martens WB; Tawil R
    Muscle Nerve; 2016 Oct; 54(4):696-701. PubMed ID: 26840230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.